KOSDAQBiotech & Pharma049180

Cellumed

₩1,009 0.00%2026-11-18 close
Market Cap
₩84B
Turnover
₩0
Volume
0 shares
Shares out.
83.2M
PER
—
PBR
—
EPS
-₩77
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrowing, but Capital Repair Remains the Test

Cellumed posted a quarterly operating profit in the second quarter of 2026 but returned to an operating loss in the third quarter, leaving capital impairment and the listing review as the main open issues.

  1. 1

    The operating loss narrowed to KRW 5.13 billion in 2025 from KRW 6.83 billion in 2024, while sales of KRW 140.2 billion were the largest of 2022 to 2025.

  2. 2

    Operating profit of KRW 1.56 billion in the second quarter of 2026 was followed by an operating loss of KRW 1.07 billion in the third quarter.

  3. 3

    Total equity was KRW 8.39 billion at end-2025 against total liabilities of KRW 52.5 billion, a debt-to-equity ratio of 625.9%.

  4. 4

    A disclaimer of opinion on the 2025 audit triggered a delisting criterion, and the exchange granted an improvement period through April 10, 2027.

  5. 5

    A selective capital reduction that cancels shares held only by the largest shareholder goes to an extraordinary shareholder meeting on November 27, 2026.

02

Business structure

Cellumed runs a biomedical device business and a construction and machinery equipment business.

The biomedical side centers on skin and bone grafts, including the Rafugen DBM bone-regeneration device, the Dental Powder allograft, acellular dermal matrix (ADM) grafts and Bio BMP2, a bone morphogenetic protein product, according to the company profile.

Celluderm Gen, an injectable ADM graft, was reported in January 2026 as developed and being prepared for commercialization. The construction equipment business is run through a subsidiary, which reportedly generated KRW 62.1 billion in sales in the first half of 2025.

That subsidiary has won large projects including an apartment project for Korea Land & Housing Corporation in Wonju and the T2 IOC construction project for Korean Air, and a September 2025 report put its backlog at roughly KRW 140 billion.

The company said second-half growth would center on the apartment redevelopment market. Customers fall into two groups: construction project owners and orthopedic and regenerative medicine clinics.

On the biomedical side, the company described five enzymes for mRNA vaccine production developed alongside a GMP facility, and reports said development work is being outsourced to a German partner. Secondary battery and electric two-wheeler projects were also reported as under way.

A business profile service groups Cellumed with small companies in allograft and ADM materials. Unlike pipeline-driven biotech firms, Cellumed's results combine implant product sales with its construction subsidiary, so the two segments drive earnings for different reasons.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩37.3B₩1.4B3.9%
2025Q4₩28.3B-₩600M−2.3%
2026Q1₩23.4B-₩1.6B−6.7%
2026Q2₩30.8B₩1.6B5.1%
2026Q3₩24.4B-₩1.1B−4.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩122.1B-₩2.7B-₩5.6B−2.2%−10.3%69.2%
2023₩95.6B-₩10.5B-₩37.3B−10.9%−166.1%188.8%
2024₩129.1B-₩6.8B-₩31.5B−5.3%−359.4%675.0%
2025₩140.2B-₩5.1B-₩2.2B−3.7%−26.7%625.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On audited annual filings, consolidated sales fell from KRW 122.1 billion in 2022 to KRW 95.6 billion in 2023, a 21.7% decline, then rose to KRW 129.1 billion in 2024 (up 35.1%) and KRW 140.2 billion in 2025 (up 8.6%).

Sales grew in two consecutive years, 2024 and 2025, and 2025 was the largest year of the 2022 to 2025 period. Operating losses ran for four consecutive years: KRW 2.73 billion in 2022, KRW 10.5 billion in 2023, KRW 6.83 billion in 2024 and KRW 5.13 billion in 2025.

Operating margin worsened from -2.2% in 2022 to -10.9% in 2023, then improved to -5.3% in 2024 and -3.7% in 2025, so 2025 combined higher sales with a smaller operating loss.

Net losses attributable to controlling shareholders were far larger than operating losses in 2023 and 2024, at KRW 37.3 billion and KRW 31.5 billion, before narrowing to KRW 2.24 billion in 2025.

Total net loss including non-controlling interests was KRW 37.9 billion in 2023, KRW 31.8 billion in 2024 and KRW 2.18 billion in 2025, which points to large non-operating burdens in those years. Press coverage has cited a KRW 17.6 billion settlement in a US royalty lawsuit as a source of financial pressure.

Quarterly results swing sharply. The third quarter of 2025 showed sales of KRW 37.3 billion, operating profit of KRW 1.45 billion and net profit attributable to controlling shareholders of KRW 7.96 billion, a gap that again indicates large non-operating items.

The fourth quarter fell 24.2% quarter on quarter to KRW 28.3 billion in sales, with an operating loss of KRW 649 million and an attributable net loss of KRW 6.2 billion. The first quarter of 2026 recorded sales of KRW 23.4 billion and an operating loss of KRW 1.58 billion.

The second quarter rose 31.6% to KRW 30.8 billion, with operating profit of KRW 1.56 billion and attributable net profit of KRW 2.6 billion. The third quarter of 2026 brought sales of KRW 24.4 billion, down 34.7% year on year, an operating loss of KRW 1.07 billion and an attributable net loss of KRW 1.17 billion.

Attributable net losses over the last four quarters total KRW 6.45 billion. At end-2025, total liabilities were KRW 52.5 billion and the debt-to-equity ratio was 625.9%, and operating cash flow was negative in every year from 2022 to 2025, at -KRW 3.86 billion in 2025.

05

Industry analysis

Demand from two end markets drives the business. The biomedical side depends on orthopedic and regenerative surgery demand for bone and skin grafts, and the company said production rose after May 2025.

The construction equipment side depends on contract awards for apartment redevelopment and large public and private sites such as airport projects. The subsidiary cited the Wonju apartment project for Korea Land & Housing Corporation and the T2 IOC project for Korean Air as drivers of first-half results.

A September 2025 report put the backlog at roughly KRW 140 billion. Because the two markets follow different cycles, weakness in one can be partly offset by the other.

Construction awards are sensitive to project schedule changes, however, which can widen quarterly swings; the 2026 sequence of KRW 23.4 billion, KRW 30.8 billion and KRW 24.4 billion in quarterly sales illustrates this.

Among competitors, small biotech companies handling allograft and acellular dermal matrix products are classed as similar companies. Cellumed differs from pipeline-driven biotech firms because implant product sales and construction subsidiary orders both feed reported earnings.

On regulation, press coverage described a tougher exchange stance toward listed companies with capital impairment above 50%.

06

Outlook

In early 2026, when the rights offering closed, the company said it would use capital restructuring, liquidity and profit-focused management to make 2026 the first year of a turnaround.

A second-quarter operating profit was followed by a third-quarter operating loss, so whether the turnaround is sustained has not yet been shown.

On products, commercialization of Celluderm Gen is under way, and the company expected production gains and the construction backlog to support second-half sales, according to a September 2025 report.

On capital, the selective capital reduction was disclosed as a way to offset accumulated deficits and improve the capital structure. Once completed, the share count and paid-in capital would fall, and the largest shareholder's stake would decline on disclosed figures.

On litigation, the status of the unpaid balance of the US royalty settlement will affect cash flow. On audit, a clean opinion in the 2026 fiscal year audit report is cited as a precondition for remaining listed. The exchange's improvement period runs through April 10, 2027.

The next checkpoints are therefore the 2026 audit opinion, capital impairment after the reduction, and whether full-year operating results return to a profit.

07

Valuation

PER
—
PBR
—
ROE
-32.1%
EPS
-₩77
BPS
—
Dividend per share
₩0

Current market value sits well above the book value attributable to controlling shareholders at end-2025, a structure in which the premium over net asset value is large. That suggests the share price reflects expectations of business normalization more than asset value.

Because attributable net losses have continued over the last four quarters, PER based on earnings cannot be calculated. On an annual basis, operating losses ran for four consecutive years from 2022 to 2025, and the loss narrowed in 2025.

A quarterly operating profit appeared once, in the second quarter of 2026, and the third quarter returned to a loss. Dividend capacity is structurally limited given thin equity under capital impairment. Reports described large share price swings after the January 2026 rights offering and change of largest shareholder.

Valuation interpretation depends on whether the capital structure normalizes and whether profits hold on an annual basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Second-quarter 2026 profit

Second-quarter 2026 sales rose 31.6% quarter on quarter to KRW 30.8 billion, with operating profit of KRW 1.56 billion and attributable net profit of KRW 2.6 billion. A profitable quarter after a run of operating losses is cited as evidence of possible business normalization. The third-quarter operating loss, however, means sustained profitability has not yet been shown.

Capital injection and change of largest shareholder

A third-party rights offering in January 2026 raised KRW 17 billion, and the largest shareholder changed to Tide Land Mark Association 1. The company said proceeds would go to KRW 13.3 billion of debt repayment and KRW 3.7 billion of operating funds.

The company presented the offering as a base for capital restructuring and profit-focused management, and a selective reduction now aims to lower the reported capital impairment ratio.

Construction backlog and product pipeline

The construction subsidiary reportedly generated KRW 62.1 billion in sales in the first half of 2025, and a September 2025 report put its backlog at roughly KRW 140 billion. Implant production reportedly rose after May 2025. Celluderm Gen, an injectable ADM product, is being prepared for commercialization. Whether the backlog converts into reported sales is the next point to check.

09

Bear factors

Four years of operating losses and thin equity

Operating losses ran for four consecutive years from 2022 to 2025, and at end-2025 total equity was KRW 8.39 billion against total liabilities of KRW 52.5 billion. The debt-to-equity ratio rose from 188.8% in 2023 to 625.9% in 2025, increasing financial strain.

Operating cash flow was negative in every year from 2022 to 2025, so the core business did not generate cash in any of those years.

Audit opinion and listing review

A disclaimer of opinion on the 2025 audit led to a delisting criterion arising on March 31, 2026. The company filed an objection, and the exchange granted an improvement period through April 10, 2027. Press coverage said that without a clean opinion in the 2026 audit report, avoiding delisting would be difficult.

Capital impairment above 50% at both the 2024 and 2025 year-ends was also cited as a basis for a substantive listing review.

Settlement payments and governance uncertainty

Press reports said part of the KRW 17.6 billion settlement in a US royalty lawsuit was not repaid on schedule, with a balance of about KRW 13 billion left outstanding. Concern was raised that rights offering proceeds might be used differently from the original purpose.

The company also received penalty points as an insincere disclosure filer after withdrawing a small rights offering, and a planned acquisition by a group affiliate fell through.

10

Risk factors

Listing continuity risk

The delisting criterion tied to the disclaimer of opinion has not yet been resolved. The improvement period runs through April 10, 2027, and the company must then submit an implementation report and expert confirmation within 15 business days.

Reports describe the exchange as strict toward companies that fail listing criteria, which makes a clean audit opinion the largest variable. Reports also say trading suspension continues during the improvement period.

Financial and litigation risk

With a debt-to-equity ratio of 625.9% and total equity of KRW 8.39 billion, another loss could deepen capital impairment. Reports say unpaid balances of the US royalty settlement remain a cash burden.

The settlement reportedly carries a condition that, if not performed, the full judgment amount and legal costs become payable, which adds to the risk.

Use of funds and governance risk

The January 2026 rights offering changed the largest shareholder, and if the selective reduction passes, that holder's stake falls from 33.87% to 14.63% on disclosed figures. Concern has been raised about whether proceeds were used for the stated debt repayment and operating needs. Until governance settles, transparency on fund use remains important.

11

What to watch next

  1. November 27, 2026

    The extraordinary shareholder meeting takes up the selective capital reduction, which cancels 18,761,339 shares held by the largest shareholder, a 22.54% reduction ratio. Passage determines the change in paid-in capital and the largest shareholder's stake.

  2. December 15, 2026

    This is the reduction record date. New shares are scheduled to list on January 5, 2027, and the disclosed trading suspension period runs from December 14, 2026 to January 4, 2027.

  3. Late March 2027

    The 2026 fiscal year audit report and annual business report are expected. The 2025 opinion, published on March 31, triggered the delisting criterion, so whether a clean opinion returns and whether full-year 2026 operating results turn profitable are the key points.

  4. April 10, 2027

    The exchange's improvement period ends. Within 15 business days afterward, the company must submit its implementation report and expert confirmation, and the exchange then decides on delisting.

12

Overall view

Cellumed combines a biomedical graft business with a construction equipment subsidiary, and its sales grew from KRW 122.1 billion in 2022 to KRW 140.2 billion in 2025.

Operating losses nonetheless ran for four consecutive years through 2025, equity at end-2025 was only KRW 8.39 billion, and the debt-to-equity ratio stood at 625.9%. The second quarter of 2026 showed an operating profit, but the third quarter returned to a loss, so quarterly consistency has not been shown.

On the bull side, the KRW 17 billion rights offering, the change of largest shareholder and the planned selective capital reduction are efforts to reshape the capital structure.

On the bear side, the delisting criterion tied to the disclaimer of opinion, the improvement period through April 10, 2027, and reports of unpaid settlement installments keep listing requirements and cash burdens prominent.

Valuation rests on a market value far above book value attributable to controlling shareholders, with no earnings-based PER available, so the assessment depends heavily on whether capital normalizes.

The next checkpoints are the November 27, 2026 extraordinary shareholder meeting, the 2026 fiscal year audit report expected around late March 2027, and the end of the improvement period on April 10, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. jobkorea.co.kr
  3. biotimes.co.kr
  4. pharmnews.com
  5. biotimes.co.kr
  6. news2day.co.kr
  7. medicopharma.co.kr
  8. biotimes.co.kr
  9. marketin.edaily.co.kr
  10. sentv.co.kr
  11. kr.investing.com
  12. kr.investing.com
  13. investing.com
  14. ggilbo.com
  15. thevc.kr
  16. news.nate.com
  17. judal.co.kr
  18. thebell.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis